Medivation Inc. (NASDAQ:MDVN)’s share price reached a new 52-week high on Thursday . The company traded as high as $64.39 and last traded at $63.63, with a volume of 538,369 shares changing hands. The stock had previously closed at $64.08.

A number of equities analysts have weighed in on MDVN shares. Canaccord Genuity reissued a “hold” rating on shares of Medivation in a research report on Wednesday, April 6th. Leerink Swann reissued a “market perform” rating on shares of Medivation in a research report on Sunday, April 10th. BMO Capital Markets started coverage on shares of Medivation in a research report on Monday, April 11th. They issued a “market perform” rating and a $47.00 price objective for the company. Vetr cut shares of Medivation from a “hold” rating to a “sell” rating and set a $49.59 price objective for the company. in a research report on Monday, April 18th. Finally, Cowen and Company reissued a “hold” rating on shares of Medivation in a research report on Sunday, April 17th. One equities research analyst has rated the stock with a sell rating, eight have assigned a hold rating, fourteen have issued a buy rating and one has given a strong buy rating to the stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $72.08.

The stock’s 50-day moving average is $61.24 and its 200-day moving average is $49.76. The company has a market capitalization of $10.49 billion and a price-to-earnings ratio of 42.80.

In other news, SVP Andrew Kenneth William Powell sold 2,578 shares of the firm’s stock in a transaction dated Monday, June 6th. The shares were sold at an average price of $60.42, for a total transaction of $155,762.76. Following the completion of the transaction, the senior vice president now directly owns 28,517 shares of the company’s stock, valued at approximately $1,722,997.14. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO Rick Bierly sold 10,340 shares of the firm’s stock in a transaction dated Friday, May 6th. The stock was sold at an average price of $59.76, for a total transaction of $617,918.40. Following the transaction, the chief financial officer now directly owns 35,059 shares of the company’s stock, valued at $2,095,125.84. The disclosure for this sale can be found here.

Other institutional investors have added to or reduced their stakes in the company. BlackRock Advisors LLC increased its position in Medivation by 3.3% in the fourth quarter. BlackRock Advisors LLC now owns 1,245,350 shares of the biopharmaceutical company’s stock worth $60,201,000 after buying an additional 40,001 shares during the last quarter. Westfield Capital Management Co. LP increased its position in Medivation by 30.5% in the fourth quarter. Westfield Capital Management Co. LP now owns 1,403,498 shares of the biopharmaceutical company’s stock worth $67,845,000 after buying an additional 327,652 shares during the last quarter. KBC Group NV increased its position in Medivation by 98.7% in the fourth quarter. KBC Group NV now owns 32,177 shares of the biopharmaceutical company’s stock worth $1,556,000 after buying an additional 15,984 shares during the last quarter. I.G. Investment Management LTD. increased its position in Medivation by 10.2% in the fourth quarter. I.G. Investment Management LTD. now owns 56,420 shares of the biopharmaceutical company’s stock worth $2,727,000 after buying an additional 5,200 shares during the last quarter. Finally, Advisors Asset Management Inc. increased its position in Medivation by 16.6% in the fourth quarter. Advisors Asset Management Inc. now owns 25,952 shares of the biopharmaceutical company’s stock worth $1,255,000 after buying an additional 3,688 shares during the last quarter.

Medivation, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapies to treat serious diseases for which there are limited treatment options. The Company, in collaboration with Astellas Pharma, Inc (Astellas), has one commercial product, XTANDI (enzalutamide) capsules (XTANDI).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.